$12.99
Value $823M
INMD and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$12.99
Value $823M
$138.69
Value $343B
InMode (INMD) has a market value of $823M and Merck & Company (MRK) $343B. Over the last year, with dividends, INMD moved -6.6% and MRK +53.8%. The P/E is 8.8 for INMD and 139.8 for MRK. Dividend yield: INMD none, MRK 2.45%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
INMD$823M
MRK$343B
MRK is 417 times INMD
Revenue, 12 months
INMD$370M
MRK$67.4B
MRK is 182 times INMD
Net income, 12 months
INMD$94M
MRK$2.5B
MRK is 26 times INMD
Operating margin
INMD23.1%
MRK–
ROIC
INMD9.9%
MRK3.9%
6.0 points apart
P/E
INMD8.8
MRK139.8
MRK is 16 times INMD
Dividend yield
INMD0.0%
MRK2.5%
2.5 points apart
5-year return
INMD-86.2%
MRK+95.6%
181.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
INMD-86.2%
MRK+95.6%
| Period | INMDWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -6.6%Price -6.6% | +53.8%Price +49.4% |
| 3 years since November 17, 2023 | -41.2%-16.2% a yearPrice -41.2% | +49.4%+14.3% a yearPrice +36.3% |
| 5 years since November 17, 2021 | -86.2%-32.7% a yearPrice -86.2% | +95.6%+14.4% a yearPrice +67.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
INMDInModeMRKMerck & Company
| Price | $12.99 | $138.69 |
|---|---|---|
| Market value | $823M | $343B |
| Enterprise value (EV) | $437M | $387B |
| P/E | 8.8 | 139.8 |
| P/E, 5-year median | 10.3 | 14.8 |
| P/B | 1.2 | 7.6 |
| EV/EBIT | 5.1 | 81.3 |
| Free cash flow yield | 10.2% | 4.3% |
| Revenue, 12 months | $370M | $67.4B |
|---|---|---|
| Net income, 12 months | $94M | $2.5B |
| Free cash flow, 12 months | $84M | $14.7B |
| Earnings per share, 12 months | $1.43 | $0.98 |
| Revenue growth, year on year | -6.2% | 1.3% |
| Revenue growth a year, past | +12.4%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | +10.0%over 5 years | +21.2%over 5 years |
| Gross margin | 78.5% | 71.8% |
|---|---|---|
| Operating margin | 23.1% | – |
| Net margin | 25.3% | 3.6% |
| ROIC | 9.9% | 3.9% |
| ROE | 13.7% | 5.2% |
| Cash | $386M | $9.7B |
|---|---|---|
| Total debt | $8.2M | $53.8B |
| Net debt / EBITDA | -4.5 | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | 15.5% | 1.5% |
| Shareholder yield | 15.5% | 3.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($343B) is about 416.8 times InMode ($823M), at today's prices.
Since November 17, 2021, INMD's price moved -86.2% and MRK's +67.9%. With dividends: INMD -86.2% (-32.7% a year), MRK +95.6% (+14.4% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for InMode and 2.45% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 8.8 for INMD and 139.8 for MRK. The median of the last five years was 10.3 and 14.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 25.3% for InMode and 3.6% for Merck & Company, and the operating margin 23.1% and –. Revenue was $370M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.